Guardant Health, Inc. (GH) Stock Score, Valuation & Financial Research
Guardant Health, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for GH
Guardant Health, Inc. currently has a Wall Street Score of 28/100. The stored market price is $157.38. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Guardant Health, Inc. does
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnec
GH financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $157.38
- Market capitalization:
- $21.12B
- Revenue:
- $1.18B
- Net income:
- $-453.4M
- Free cash flow:
- $-233.1M
- Cash:
- $1.05B
- Total debt:
- $1.70B
- EPS:
- -3.32
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 37/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-233.1M, showing cash burn in the current stored period.
- The balance sheet shows $1.05B of cash versus $1.70B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.3 points: GH increased 0.3 points because Revenue improved by 6.9 points.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-13.
How to research GH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.